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ABSTRACT  
Background: Myeloma is consistently preceded by premalignant MGUS. In >5% of MGUS 
patients there is a second MGUS clone (BGUS), yet, at myeloma diagnosis, presentation of 
biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma 
eradicates coexisting MGUS. 
 
Methods: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly 
diagnosed myeloma patients enrolled in recent UK clinical trials. 
 
Results: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 
(0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates 
coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed 
in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did 
not inhibit the myeloma plasma cell clone in BGMy. 
 
Conclusions: Myeloma eliminates the majority of competing MGUS, and when it does not, the 
MGUS clone is substantially reduced in size. 
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INTRODUCTION 
Myeloma and the asymptomatic precursor that consistently precedes it, monoclonal gammopathy 
of undetermined significance (MGUS) (Landgren et al, 2009; Weiss et al, 2009), are characterised 
by monoclonal plasma cells in the bone marrow and monoclonal antibody (MAB) in blood. In a 
population based study of 12,482 persons, prevalence of MGUS was 3.7% in blacks, 2.3% in 
whites and 1.8% in Hispanics, and within these MGUS populations, the prevalence of two MGUS 
clones – termed biclonal gammopathy of undetermined significance (BGUS) (Kyle et al, 1981) – 
was 15.4%, 6.8% and 12.8%, respectively (Landgren et al, 2014). A proportion of new myeloma 
diagnoses also exhibit two MABs in immunofixation electrophoresis (IFE), termed myeloma with 
biclonal gammopathy (BGMy). This represents progression of one BGUS clone to active myeloma 
and the continued presence of a secondary MGUS clone (Kyle et al, 2003; Kyle et al, 1981). Given 
that the prevalence of MGUS in the general population – at the mean age of myeloma diagnosis – 
is ~5% (Dispenzieri et al, 2010; Wadhera & Rajkumar, 2010), and prevalence of BGUS amongst 
all MGUS is greater than 5% (Landgren et al, 2014), one would also expect more than 5% of 
myeloma cases to be BGMy. The frequency of BGMy remains uncertain (Garcia-Garcia et al, 
2015; Guastafierro et al, 2012; Kyle et al, 1981; Nilsson et al, 1986; Riddell et al, 1986). In a 
review of 1,027 myeloma diagnoses in one centre, 2% of cases were BGMy (Kyle et al, 2003). 
This lower than expected figure warrants validation as it implies that when myeloma arises in an 
individual with BGUS, the malignant myeloma clone eliminates the competing MGUS clone. Here, 
in the largest study of its kind, we assessed 6,399 newly diagnosed myeloma patients entered into 
three multi-centre UK clinical trials to determine the frequency, and MAB sizes of, BGMy at 
myeloma diagnosis.  
 
  
  
 4 
MATERIALS AND METHODS 
Trial patients  
BGMy patients were identified from 6,399 newly diagnosed myeloma patients enrolled in one of 
the following multi-centre, phase III trials: the UK MRC Myeloma IX trial (N=1693; 
ISRCTN68454111); the CRUK Myeloma XI trial up to an induction randomisation date of 23 July 
2015 (N=3880; ISRCTN49407852); or, the UK NIHR TEAMM Trial up to a randomisation date of 
23 July 2015 (N=826; ISRCTN51731976).  
 
Laboratory tests 
MABs in serum were identified by IFE (Sebia, France) and quantified by protein zone 
electrophoresis and densitometry (SPE; Interlab, Italy); please refer to Supplementary for more 
information. In patients with a light chain (LC) MAB without a heavy chain (HC) component (i.e., 
light chain only myeloma), MAB size was measured and monitored by involved free light chains 
(iFLCs; Binding Site, UK) expressed in g/L.  
 
Statistical analyses 
Differences between groups were analysed by one-way ANOVA for continuous variables (e.g. 
MAB size), and Chi-Square for categorical variables and frequencies. One sample t-tests were 
used to compare observed MAB sizes to previously observed mean MAB sizes in the literature; 
observed BGMy MAB sizes were compared to reported MAB sizes in MGUS (Turesson et al, 
2014) and myeloma using a combined dataset from MIX and MXI UK trials. Correlational analyses 
were conducted using Pearson’s for normally distributed data and Spearman’s Rank where data 
was skewed. Significance was accepted at p<.05. Data were analysed by IBM SPSS statistics 
version 21. 
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RESULTS 
Frequency of BGMy and demographics of BGMy patients 
58 patients had BGMy (from MIX=18; MXI=33, TEAMM=7) and 6341 had monoclonal 
gammopathy myeloma (MGMy) giving a BGMy frequency of 58/6399 patients (0.91%; 99% 
confidence interval: ±0.3%). Comparison of the 58 BGMy patients with MGMy patients in the same 
trials (Heaney et al., in submission) found no differences in age: BGMy median age [range] was 69 
[45-86] years, and MGMy was 66 [28-90] years. 
 
Distinguishing MGUS from myeloma MABs 
The frequencies and concentrations of serum MABs in all 58 BGMy patients at trial entry are 
presented in Table 1; the largest MAB is classified as the myeloma MAB and is referred to as ‘M1’, 
whereas the smaller MAB was classified as the MGUS MAB and is referred to as ‘M2’. In 4 
patients with a FLC MAB >500mg/L and intact immunoglobulin < 5g/L, the FLC MAB was selected 
as M1. M1s were 10- to 20-fold larger than M2s with median M1 IgG 36.1 g/L compared to M2 IgG 
2.6 g/L; and M1 IgA 24.1 g/L compared to M2 IgA 1.7 g/L.  
 
M1 and M2 MAB combinations in BGMy are presented in Table 2 where it can be seen that 37/58 
BGMy (65%) combinations exhibited different LC isotypes; assessment of available serum FLC 
levels in these patients (illustrated in Supplementary Figure 1) demonstrated that elevated FLC 
levels were predominantly associated with the M1 clone.   
 
In Table 2, we show that two independent IgG MABs was the most common M1 and M2 
combination (16/58 pts), but not as common as expected (27/58), and we did not observe any 
patients with two IgG MABs with the same LC isotype (15/58 expected; p<0.001; χ2=17.228). In 6 
BGMy patients with two IgG MABs, the electrophoretic mobilities of the MABs were very similar 
and so these MABs were only reliably distinguishable by their different LC isotype. Accordingly we 
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may have missed a third of the 15/58 expected IgG MAB pairs of the same LC isotype, because of 
electrophoretic mobility similarities.  
 
 
MGUS MAB isotypes and levels in BGMy compared to conventional MGUS 
The most frequent M2 was IgG (33/58) and a quarter of M2 clones (14/58) secreted IgM. The 
frequency of different M2 HC isotypes was closest to the patterns observed in two MGUS studies 
of 728 and 694 MGUS patients, rather than the different HC frequencies seen in myeloma (Kyle et 
al, 2006; Turesson et al, 2014) (Table1). There were, however, less IgG M2s than would be 
expected in a typical MGUS population (33 versus 41) and more IgM and IgA isotypes (25 versus 
16) (trend observed: p=0.092 χ2=2.83). 
 
The level of the MGUS associated MAB (M2) in BGMy was smaller than sizes reported in MGUS 
(10, 11) by 2.5-fold for IgG and 5-fold for IgA and IgM MABs (p<0.001). Thus, whereas coexistent 
MGUS (i.e., M2) did not appear to suppress the myeloma clone (i.e., M1) in BGMy, the presence 
of myeloma (M1) significantly suppressed MGUS (M2) MAB levels. The magnitude of this 
suppression is illustrated in Table 3 where 83% of M2’s were below 5 g/L compared to the 
observed 24% in a prior MGUS study. 
 
Serum levels of myeloma MABs are the same in MGMy and BGMy 
IgG was the most prevalent M1, followed by IgA, FLC and then IgD; no IgM or IgE M1’s were 
observed; please refer to Supplementary for more information. HC frequencies were very similar 
to those of 3248 patients in the same clinical trials who had MGMy (Table 1). Notably, IgG and IgA 
M1 MAB concentrations were not significantly different to those observed in the MGMy patients 
from the same trials. This indicates that the presence of a second neoplastic plasma cell clone 
(i.e., M2) does not competitively suppress the expansion of the neoplastic myeloma clone (i.e., 
M1) (Table 3). 
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DISCUSSION 
This is the largest study of BGMy frequency in a large cohort of newly diagnosed myeloma 
patients and demonstrates that myeloma eliminates or greatly suppresses coexisting MGUS. As 
the prevalence of MGUS in the general population – at the typical age of myeloma diagnosis – is 
~5% (Dispenzieri et al, 2010; Wadhera & Rajkumar, 2010) and the prevalence of BGUS amongst 
all individuals with MGUS is >5% (Landgren et al, 2014), it would also be expected that >5% of 
myeloma cases would be BGMy. However, despite rigorous central laboratory analysis, it was 
found to be just 0.91%.  
 
This shortfall is unlikely to be the result of myeloma being 5-fold more likely to arise in individuals 
with a single MGUS clone than from individuals with two MGUS clones. A recent study reported 
the rate of progression from BGUS to myeloma was approximately 1% per year, which is similar to 
the incidence of MGUS progression to myeloma (Mullikin et al, 2016). Thus, when myeloma arises 
from BGUS, in approximately 80% of cases, the other MGUS clone must be eliminated or 
suppressed below the limits of detection on IFE (0.1g/l).  
 
In the BGMy cases reported herein, MGUS associated MAB levels were smaller than expected 
levels typically observed in conventional MGUS (Turesson et al, 2014), by 2.5-fold for IgG and 5-
fold for IgA and IgM. The degree of suppression of MGUS clones in BGMy appears comparative to 
the immunoparesis of non-malignant polyclonal plasma cells (PC) that occurs in the majority of 
newly diagnosed myeloma patients (Kastritis et al, 2014; Pruzanski et al, 1980; Wang & Young, 
2001; Wangel, 1987). Of 3,248 MGMy patients from the same Myeloma IX and XI trials reported in 
this study, we found that polyclonal immunoglobulin levels were below the normal range in >80% 
of patients and levels were lower than the median level found in healthy controls by 2.5-fold for 
IgG, and 7-fold for IgA and IgM (Heaney et al, Submitted). Despite their larger relative presence, 
MGUS clones appear to only compete effectively with polyclonal PC in ~20% of cases, as 
evidenced by incidence of immunoparesis in MGUS (Turesson et al, 2014). As only a fifth of 
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MGUS clones exhibit competitiveness for the normal PC niche, we hypothesise that these are the 
only MGUS clones that survive when myeloma arises in the wider marrow environment and that 
they are subject to the same suppression of clonal size and antibody secretion as normal 
polyclonal plasma cells; this would also be applicable to the MGUS PC clone from which myeloma 
arose.  In a separate observation, we observed in this study that two IgG MABs was the most 
common BGMy combination (16/58 pts) but not as common as expected (27/58) indicating that 
the presence of IgG myeloma PC clones suppresses IgG MGUS PC clones more than IgA or IgM 
PC clones. There is evidence from both MGUS and myeloma that neoplastic IgG PC clones exert 
a greater degree of suppression on normal polyclonal IgG PC than they do on IgA and IgM 
isotypes (Bradwell et al, 2013; Katzmann et al, 2013; Ludwig et al, 2016).  
 
A limitation of our study is that we were unable to conduct longitudinal measurement of BGUS 
prior to myeloma diagnosis; this excluded the possibility of investigating elimination of MGUS 
clones at the time of myeloma clone proliferation. Future prospective studies may seek to explore 
differences between BGUS which progress to myeloma, and BGUS that do not progress to 
myeloma, and measurements should incorporate bone marrow tumour samples as well as stroma 
to investigate possible mechanisms of tumour eradication. In summary, our findings confirm that 
BGMy is rare, and the survival of a coexisting MGUS clone is hallmarked by reduced MAB size. 
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Table 1. Characteristics and frequencies of M1 and M2 in 58 BGMy patients at myeloma diagnosis, compared to expected frequencies and characteristics of MGMy and 
conventional MGUS. 
 
Monoclonal Antibody (MAB) 1 Monoclonal Antibody (MAB) 2 
HC Isotype 
Frequency 
(N)  
Proportion  
(%) 
Conc. (g/L) 
(median [range]) 
MGMy reference ranges † 
HC Isotype 
Frequency 
(N) 
Proportion 
(%) 
Conc. (g/L) 
(median [range]) 
MGUS reference ranges ‡ 
Proportion 
(%) 
Conc. (g/L) 
(median [range]) 
Kyle 
et al., 
2006 
Turesson  
et al.,  
2013 
Proportion 
(%) 
Conc. (g/L) 
(median ± SD) 
IgG 
Total  39 67.2 *36.1 [4.8-70.0]  59.9 34.4 [0.8-100.2] 
IgG 
Total 33 56.9 **2.6 [0.5-12.0] 68.9 68.8 7.0 ± 6.0 
IgGκ 
IgGλ 
26  
13  
66.7 
33.3 
32.6 [4.8-70.0] 
39.7 [10.2-60.0] 
  IgGκ 
IgGλ 
17 
16 
51.5 
48.5 
2.5 [0.5-12.0] 
2.8 [0.5-9.0] 
 
IgA 
Total  14  24.1 *25.4 [1.8-60.0] 23.6 33.0 [0.2-96.6] 
IgA 
Total 11 19.0 **1.7 [0.5-11.6] 10.8 14.7 8.0 ± 5.0 
IgAκ 
IgAλ 
8  
6  
57.1 
42.9 
26.9 [1.8-60.0] 
23.2 [3.9-53.0] 
  IgAκ 
IgAλ 
5 
6 
45.5 
54.5 
1.3 [0.5-3.9] 
2.5 [0.5-11.6] 
 
IgD 
Total  1  1.7 2.6 [2.6-2.6] 1.7 4.2 [0.2-36.9] 
IgM 
Total 14 24.1 **1.3 [0.5-6.0] 17.2 16.2 7.0 ± 6.0 
IgDκ 
IgDλ 
0  
1  
0.0 
100 
- 
2.6 [2.6-2.6] 
  IgMκ 
IgMλ 
12 
2 
85.7 
14.3 
1.3 [0.5-6.0] 
1.6 [0.6-2.7] 
 
FLC 
Total  4 6.9 1.0 [0.5-1.9] 13.1 2.6 [0.02-46.7] 
 FLCκ 
FLCλ 
3  
1  
75.0 
25.0 
1.4 [0.5-1.9] 
0.7 [0.7-0.7] 
  
LC Isotype 
Frequency 
(N)  
Proportion  
(%) 
Conc. (g/L) 
(median [range]) 
MM reference proportion † 
(%) 
LC Isotype 
Frequency 
(N) 
Proportion 
(%) 
Conc. (g/L) 
(median [range]) 
MGUS reference proportion (%) 
Kyle et al., 2006 
κ 37  63.8 26.0 [0.5-70.0] 66.0 κ 34 58.6 1.8 [0.4-12.0] 62.0 
λ  21  36.2 27.0 [0.7-60.0] 34.0 λ 24 41.4 2.7 [0.5-11.6] 37.9 
 
† Reference ranges aggregated from 3248 patients with MGMy diagnosed at entry into Myeloma IX and Myeloma XI trials; dataset cut-off June 2013. 
‡ Reference ranges derived from 728 MGUS patients (Turesson et al, 2013), or 694 MGUS patients (Kyle et al, 2006). 
* Significant difference between M1 and M2 concentration (IgG p<0.001; IgA p<0.001)   
** Significant difference between M2 concentration and expected MAB concentration in MGUS (IgG p<0.001; IgA p<0.001; IgM p<0.001) (Turesson et al, 2013). No significant 
differences observed between M1 and expected MAB concentrations in MGMy (p>0.05) based on observations from Myeloma IX and XI.  
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Table 2. Frequency of M1 and M2 combinations observed in BGMy. 
 
MAB 1 MAB 2 
MAB 2 Frequency MAB 2 Proportion 
Observed BGMy 
frequency (N) 
Expected MGUS† 
frequency (N) 
Observed BGMy 
proportion (%) 
Expected MGUS† 
proportion (%) 
IgG κ 
[N=26] 
IgG κ 0* 12 0 46 
IgG λ 10 6 38 23 
IgA κ 3 3 12 10 
IgA λ 4 1 15 5 
IgM κ 7 3 27 11 
IgM λ 2 1 8 5 
IgG λ 
[N=13] 
IgG κ 6 6 46 46 
IgG λ 0 3 0 23 
IgA κ 2 1 15 10 
IgA λ 2 1 15 5 
IgM κ 3 1 23 11 
IgM λ 0 1 0 5 
IgA κ 
[N=8] 
IgG κ 5 4 63 46 
IgG λ 1 2 13 23 
IgA κ 0 1 0 10 
IgA λ 0 0 0 5 
IgM κ 2 1 25 11 
IgM λ 0 0 0 5 
IgA λ 
[N=6] 
IgG κ 4 3 67 46 
IgG λ 2 1 33 23 
IgA κ 0 1 0 10 
IgA λ 0 0 0 5 
IgM κ 0 1 0 11 
IgM λ 0 0 0 5 
IgD λ IgG κ 1    
LCO κ IgG λ 3    
LCO λ IgG κ 1    
 
† Reference range proportions obtained from Turesson et al, (2014), with assumed 2:1 proportion of kappa:lambda for 
each heavy chain isotype. 
Note: Due to relatively low frequency, data from 1 patient with IgD MAB 1, and 3 patients with FLC MAB 1 not shown. 
* Chi-Squared analyses revealed significant differences between the observed frequency of IgGκ pairs in BGMy 
compared to those expected in MGUS (p<0.001; χ2=15.60). A trend (p=0.065; χ2=3.391) was observed for frequency 
of observed IgGλ pairs in BGMy and those expected in MGUS. 
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Table 3. Comparison of M1 and M2 concentrations in BGMy with expected MAB sizes in conventional MGMy, and 
MGUS.   
Size  M1 
Proportion & 
Frequency* 
Expected 
proportion 
in MGMy †**  
M2 
Proportion & 
Frequency 
Expected 
proportion 
in MGUS ‡  
<4.99g/L  7% 
[N=4] 
7% 
 
 83% 
[N=48] 
24% 
5.00g/L - 9.99g/L  7% 
[N=4]  
5% 
 
14% 
[N=8]  
19% 
10.00g/L - 14.99g/L 7% 
[N=4] 
5% 
 
3% 
[N=2] 
33% 
15.00g/L - 19.99g/L  7% 
[N=4] 
6% 0% 
[N=0] 
18% 
20.00g/L - 24.99g/L 13% 
[N=7] 
9% 
 
0% 
[N=0] 
5% 
>25.00g/L  57% 
[N=31] 
68% 
 
0% 
[N=0] 
1% 
† Reference range represents aggregated data from patients with MGMy diagnosed at entry into Myeloma IX and 
Myeloma XI trials.  
‡ Reference range derived from 694 MGUS patients (Kyle et al, 2006). 
*Excludes 4 patients diagnosed with a FLC myeloma M1 [all 4 patients had a whole MAB < 4.99 g/L) 
**Excludes patients with FLC myeloma and non-secretory myeloma.  
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Supplementary Figure 1. FLC levels at disease presentation in BGMy patients with FLC results available (N=56 of 58 patients). 
Patients are colour coded according to the LC-isotypes of M1 and M2, respectively. The involved FLC was identified by the LC 
isotype of M1.  
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SUPPLEMENTARY METHODS 
 
Laboratory testing 
If accurate quantitation of MABs was not feasible – e.g., when a pair of MAB bands shared the 
same position on SPE (i.e., IgGκ IgGλ), or when the size of the MABs were too small to be 
detected by densitometry (limit of detection: ~1g/L) – MAB concentration was estimated from IFE, 
taking into account the size of the monoclonal bands as a proportion of total immunoglobulin of 
that HC isotype (i.e., taking into account background polyclonal immunoglobulin); this exercise 
was carried out by three experienced IFE users, independently, blind of sample timepoint, before 
agreement was reached per sample. 
 
SUPPLEMENTARY RESULTS 
MABs that may have been missed by IFE 
In this study, HC isotype frequencies for the M1 MABs were very similar to those in patients in the 
same clinical trials who had MGMy. The exception was a reduced number (4 versus 8) of 
expected FLC myeloma due to the exclusion of patients with a FLC and an intact immunoglobulin 
MAB exhibiting the same LC isotype because the MABs were presumed to derive from the same 
PC clone. Further, as discussed elsewhere, we may have missed a third of the 15 expected IgG 
MAB pairs exhibiting the same LC isotype because of very similar electrophoretic mobility. 
Similarly we may have missed 2 IgA BGMy patients. These three problems in determining the 
presence of MABs from two separate PC clones are likely to have reduced the numbers of BGMy 
detected. However the same problems apply equally to identification of BGUS and so the 
discrepancy between prevalence of BGUS in MGUS patients and prevalence of BGMy in myeloma 
patients remains at five fold. 
 
